Judging from its top line, AstraZeneca had a stellar 2024, generating an 18% increase in revenue, with 14 of the products in ...
Astrazeneca has defended the £14.7 million pay package handed to chief executive Pascal Soriot, saying the group is too big ...
The Cambridge-based pharmaceutical company behind a variety of medicines paid its chief executive Pascal Soriot £14.7 million ...
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...
AstraZeneca’s CEO Pascal Soriot has dismissed continued rumours about his departure as “fake news” as the company announced full year results showing sales growth for the first time in a decade.
AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
Pascal Soriot, chief executive officer of the UK’s biggest drugmaker, was responding to reports that the company’s relationship with the new Labour government has soured, with Britain being ...
Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed earlier this week, saying Labour failed to match the previous government’s ...
Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...
AstraZeneca has halted plans to build a £450 million vaccine plant in the UK due to decreased government support, prompting the company to urge the nation to improve its business investment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results